Titre :
|
Exploring the medical cannabis prescribing behaviours of French general practitioners
|
Auteurs :
|
Tangui Barré, Aut. ;
Hélène Venturino, Aut. ;
V. DI BEO, Aut. ;
Patrizia CARRIERI, Aut. ;
Anne-Laure Pelissier, Aut.
|
Année de publication :
|
2023
|
Pagination :
|
299-303
|
Note générale :
|
In Drug and Alcohol Review, Vol. 42, N° 2, février 2023.
|
Langues:
|
Anglais
|
Mots-clés :
|
SANTEPSY
ATTITUDE
;
CANNABIS
;
ENQUETE
;
MEDECIN GENERALISTE
;
PRATIQUE MÉDICALE
;
PRESCRIPTION MEDICALE
;
USAGE THERAPEUTIQUE
|
Résumé :
|
Cannabis use in all its forms, including for therapeutic purposes, is criminalised in France. Users may be sentenced to up to 1 year in prison and fined 3750€. The only exception for legal therapeutic use of cannabis is through the ongoing 2-year long (March 2021–March 2023) nationwide experiment that aims to assess the feasibility of allowing the prescription of medical cannabis. In March 2022, 1,500 patients had already been enrolled (3,000 participants expected by 2023). The prescription of medical cannabis is limited to the following conditions: resistant neuropathic pain, certain forms of resistant epilepsy, certain resistant symptoms in oncology, palliative treatment and resistant painful spasticity. The inclusions, first medical visits and the first prescriptions of cannabis-based products in the experiment are conducted in predetermined reference centres and patients then return to these centres for compulsory follow-up visits. However, in between those visits, they can be followed-up by a physician in a hospital or a private practice (such as a general practitioner [GP]) who has completed the compulsory training for the prescription of cannabis-based products. [Extrait]
|